Last updated: September 9, 2026
PLASMANATE is a legacy plasma-derived biologic containing 5% human plasma protein fraction. Its commercial market is mature, specialized, and substantially smaller than the markets for human albumin, intravenous immunoglobulin, and coagulation products. Grifols is the principal commercial manufacturer associated with PLASMANATE in the United States. Grifols does not separately report PLASMANATE revenue, unit volume, gross margin, or backlog, so the product’s standalone financial trajectory cannot be quantified from public company filings.
PLASMANATE’s economics are driven by source-plasma availability, fractionation capacity, hospital demand for volume expansion, albumin substitution, manufacturing compliance, and competition from crystalloid fluids and human albumin. Its regulatory and intellectual-property profile is materially different from that of a newer biologic: the product is a long-established plasma derivative with limited practical patent protection and no conventional biosimilar barrier.
What is PLASMANATE and what is it used for?
PLASMANATE is Plasma Protein Fraction (Human), 5%, administered intravenously. The product contains albumin and other plasma proteins and is used primarily to restore circulating blood volume in selected patients with hypovolemia or plasma loss.
The FDA labeling identifies the product as a plasma-derived volume replacement product. It is not a recombinant biologic, monoclonal antibody, vaccine, or cell-and-gene therapy. Its clinical role overlaps with:
- Human albumin solutions, generally available in 5% and 25% concentrations
- Crystalloid fluids such as normal saline and balanced electrolyte solutions
- Synthetic colloids, where still used
- Plasma products in selected clinical circumstances
- Blood-component replacement strategies
PLASMANATE is not interchangeable with albumin for every labeled or clinical use. Its composition reflects a plasma protein fraction rather than purified albumin. The label also carries the risks associated with human plasma-derived products, including hypersensitivity reactions and the theoretical risk of transmission of infectious agents despite donor screening and viral-reduction controls (DailyMed, 2024).
PLASMANATE product profile
| Attribute |
PLASMANATE profile |
| Active product |
Plasma Protein Fraction (Human) |
| Concentration |
5% |
| Administration |
Intravenous |
| Product class |
Plasma-derived biologic |
| Primary clinical role |
Plasma-volume expansion |
| Principal commercial association |
Grifols |
| Primary competitors |
Human albumin, crystalloids, other plasma protein fractions |
| Regulatory pathway |
Biologic licensing framework |
| Dosage form |
Sterile injectable solution |
| Commercial maturity |
Legacy, established product |
Who manufactures PLASMANATE?
Grifols is the principal manufacturer and commercial supplier associated with PLASMANATE in the United States. Grifols is a major plasma-derived-products company with operations spanning plasma collection, fractionation, albumin, immunoglobulins, and specialty plasma proteins.
The product’s economics benefit from Grifols’ vertically integrated plasma network. A manufacturer that controls donor centers, testing, fractionation, fill-finish operations, and distribution has greater control over supply than a company relying on purchased plasma or contract manufacturing.
That integration also creates a high fixed-cost structure. Plasma collection, donor compensation, testing, regulatory compliance, cold-chain logistics, and fractionation facilities require substantial capital and operating expenditure regardless of the revenue generated by an individual legacy product.
How large is the PLASMANATE market?
No public source identifies a standalone global or U.S. market size for PLASMANATE. Market research reports generally group it within plasma-derived volume expanders, plasma protein products, or broader blood-plasma therapeutics.
The addressable market is structurally limited for four reasons:
- Human albumin is better established in many hospital formularies.
- Crystalloid fluids are cheaper and widely available.
- The product is used in defined clinical settings rather than chronic treatment.
- Hospitals increasingly evaluate plasma-derived products through pharmacy-and-therapeutics committees and cost-effectiveness protocols.
PLASMANATE is therefore a niche product within the wider plasma-derivatives market. Its commercial importance is more likely to arise from portfolio completeness, manufacturing utilization, and hospital-contract retention than from high standalone sales growth.
What drives PLASMANATE demand?
Hospital volume expansion
Demand is linked to surgeries, trauma care, burns, shock, and other conditions involving intravascular volume depletion. Product selection depends on the cause of volume loss, patient characteristics, local protocols, and physician preference.
Albumin availability and pricing
When albumin supply tightens or prices rise, hospitals may reassess the use of other plasma protein products. The reverse is also true. Strong albumin availability and competitive albumin pricing can reduce demand for PLASMANATE.
Crystalloid substitution
Crystalloids remain a strong economic competitor. Hospitals often use saline or balanced electrolyte solutions as first-line volume replacement because these products are inexpensive, familiar, and broadly stocked.
Plasma supply
PLASMANATE depends on human plasma collection and fractionation. The same source-plasma environment affects albumin and other plasma-derived products. Donor-center disruptions, labor costs, testing requirements, transportation delays, and regulatory restrictions can constrain supply.
Hospital procurement
The product is generally purchased through hospital wholesalers, group purchasing organizations, and institutional contracts. Contract decisions can favor suppliers with reliable availability across several plasma-derived categories, even where a single legacy product has limited demand.
What is the financial trajectory of PLASMANATE?
PLASMANATE’s standalone financial trajectory is not publicly disclosed. Grifols reports revenue by broader business categories and product groups rather than providing a separate PLASMANATE line item in its annual reports.
The relevant financial conclusions are:
- Revenue is likely mature rather than high-growth.
- Pricing power is constrained by albumin, crystalloid, and hospital-budget alternatives.
- Gross margin depends heavily on plasma procurement and manufacturing utilization.
- Revenue volatility can result from supply interruptions rather than changes in underlying clinical demand.
- Product-level profitability cannot be derived from consolidated Grifols reporting.
- The product may support fixed-cost absorption across the broader plasma fractionation portfolio.
Grifols’ financial performance is primarily influenced by higher-value and larger-volume products such as immunoglobulins and albumin. PLASMANATE is unlikely to be a material independent driver of consolidated revenue, although the product may contribute to the economics of a broader manufacturing platform (Grifols, 2023).
Financial sensitivity framework
| Driver |
Effect on PLASMANATE economics |
| Plasma collection cost |
Directly increases cost of goods sold |
| Fractionation utilization |
Higher utilization can improve unit economics |
| Albumin price |
Can shift hospital demand toward or away from PLASMANATE |
| Crystalloid pricing |
Low-cost alternatives pressure demand |
| Supply interruptions |
Can reduce revenue but increase spot-market value |
| Hospital contracts |
Affect volume and price realization |
| Regulatory compliance |
Raises fixed and variable manufacturing costs |
| Product discontinuation risk |
Increases if demand cannot support dedicated operations |
When does PLASMANATE lose exclusivity?
PLASMANATE is a long-established plasma-derived product, and its original exclusivity period expired decades ago. The commercial question is not loss of a current composition-of-matter patent. It is whether another manufacturer can obtain approval, establish a compliant plasma supply, validate manufacturing, and secure hospital distribution.
Traditional small-molecule patent analysis has limited value for PLASMANATE. The product’s practical barriers are manufacturing and regulatory rather than patent-based.
Orange Book status
PLASMANATE is not generally analyzed as an Orange Book-style small-molecule product with a conventional patent-and-exclusivity timetable. Plasma-derived biologics are principally governed through biologics licensing and related FDA biologic-product systems rather than the standard ANDA framework used for many generic drugs.
An Orange Book listing should not be treated as the primary indicator of PLASMANATE’s market protection. FDA biologic licensing records, product labeling, manufacturing authorization, and facility compliance are more relevant.
Biosimilar risk
Biosimilar substitution is not the central competitive risk for PLASMANATE. A plasma protein fraction is a complex biological mixture, and a follow-on product would face analytical, clinical, manufacturing, and regulatory comparability issues that differ from those for a defined recombinant protein.
A competitor could pursue a separately licensed plasma-derived product, but that route would require:
- Access to qualified human plasma
- Donor screening and testing systems
- Validated fractionation processes
- Viral inactivation and clearance controls
- Comparable quality specifications
- FDA manufacturing inspection readiness
- Commercial distribution and hospital adoption
The result is a high operational barrier despite limited patent protection.
What patents protect PLASMANATE?
No current patent estate appears to be the main commercial protection for PLASMANATE. The product’s original formulation and clinical concept are longstanding. Any historical patents associated with plasma fractionation, stabilization, containers, or processing would generally have expired or have limited relevance to present-day market exclusivity.
Potentially relevant IP categories include:
| IP category |
Commercial relevance |
| Plasma fractionation |
May protect process improvements but is unlikely to protect the legacy product broadly |
| Viral inactivation |
Could protect newer process steps, subject to claim scope and expiration |
| Stabilizers and excipients |
May apply to particular formulations |
| Container systems |
May protect packaging or delivery components |
| Manufacturing know-how |
Often more important than issued patents |
| Quality-control methods |
Can create operational advantages without blocking competitors |
| Trade secrets |
May protect process parameters and yield optimization |
For PLASMANATE, proprietary know-how, regulatory history, manufacturing scale, and plasma access are more important than an enforceable patent thicket.
What manufacturing and IP barriers affect market entry?
A new entrant would need to solve the supply chain before competing on price. Human plasma must be collected from qualified donors, tested, transported, pooled, fractionated, purified, stabilized, filled, inspected, and released under validated controls.
The main barriers are:
- Plasma collection infrastructure
- FDA-compliant donor screening
- Viral safety and pathogen-reduction controls
- Consistent protein composition
- Batch-to-batch quality control
- Facility validation and inspection
- Adequate manufacturing scale
- Hospital contracting and distribution
These barriers favor established plasma companies. They also make a low-volume legacy product difficult to launch economically unless it is produced within a larger plasma-derived portfolio.
What litigation and settlement agreements affect PLASMANATE?
No major publicly reported Paragraph IV litigation or settlement agreement is generally associated with PLASMANATE. That outcome is consistent with the product’s age and its lack of a conventional patent-driven generic-entry model.
The principal legal risks are more likely to involve:
- Product liability
- Manufacturing deviations
- Labeling and pharmacovigilance
- Plasma-donor compliance
- Supply contracts
- FDA inspection findings
- Quality-system enforcement
- Distribution and shortage obligations
There is no clear basis for treating Paragraph IV litigation as a material current market event for PLASMANATE.
How does PLASMANATE compare with albumin and crystalloid fluids?
| Factor |
PLASMANATE |
Human albumin |
Crystalloids |
| Product type |
Plasma protein fraction |
Purified plasma albumin |
Electrolyte solution |
| Plasma-derived |
Yes |
Yes |
No |
| Manufacturing complexity |
High |
High |
Lower |
| Typical cost position |
Higher than crystalloids |
Often high |
Low |
| Supply risk |
Plasma-dependent |
Plasma-dependent |
Generally lower |
| Clinical familiarity |
Established but niche |
Broad |
Very broad |
| Patent protection |
Minimal practical protection |
Product and process IP may vary |
Usually limited |
| Biosimilar relevance |
Limited |
Limited to moderate depending on product |
Not applicable |
| Main commercial risk |
Niche demand and supply cost |
Plasma availability and pricing |
Commodity pricing |
Albumin has stronger clinical and commercial recognition and a larger global market. Crystalloids have the strongest cost position. PLASMANATE occupies a narrower middle position, supported by specific institutional demand and the availability of a plasma-protein alternative.
What is the outlook for PLASMANATE revenue?
The most likely base case is stable-to-declining nominal revenue with episodic increases during plasma shortages, albumin constraints, or institutional supply disruptions. Sustained high growth is unlikely without a change in clinical guidelines, a major supply dislocation affecting competitors, or a new commercial positioning strategy.
Base-case outlook
- Mature demand
- Limited pricing expansion
- Continued competition from albumin and crystalloids
- Revenue dependent on Grifols’ portfolio and manufacturing decisions
- Low probability of meaningful patent-driven price erosion
- Moderate risk of SKU rationalization if volume falls below economic thresholds
Upside scenario
PLASMANATE could benefit from constrained albumin supply, broader use of plasma-protein volume expansion, or hospital protocols that favor plasma protein fraction products in selected patients.
Downside scenario
Revenue could contract if hospitals substitute crystalloids, consolidate purchasing around albumin, or remove the product from formularies. A manufacturing interruption could also reduce availability, although temporary scarcity might support pricing in limited channels.
Key Takeaways
- PLASMANATE is a mature 5% human plasma protein fraction used for intravenous volume expansion.
- Grifols is the principal commercial manufacturer associated with the product.
- Standalone revenue, volume, margin, and market-share data are not publicly disclosed.
- Its market is niche and materially smaller than the markets for albumin and immunoglobulins.
- Crystalloids create strong price pressure, while albumin is the main plasma-derived comparator.
- Patent expiry is not the central commercial issue. Manufacturing scale, plasma supply, regulatory compliance, and hospital access are more important.
- PLASMANATE does not present a conventional Orange Book or Paragraph IV generic-entry profile.
- Biosimilar competition is limited in practical terms, but separately licensed plasma-derived competition remains possible.
- The most probable financial trajectory is mature, stable-to-declining revenue with volatility tied to plasma and albumin supply conditions.
- Product-level profitability cannot be calculated from Grifols’ public financial reporting.
FAQs
Is PLASMANATE the same as albumin?
No. PLASMANATE is a 5% plasma protein fraction containing albumin and other plasma proteins. Human albumin products are more highly purified and are marketed as defined albumin solutions.
Is PLASMANATE still FDA approved?
PLASMANATE has an established FDA-regulated biologic product history and remains associated with FDA labeling and U.S. commercial supply information. Current availability can vary by manufacturer production and distribution conditions.
Can generic drug companies launch a generic version of PLASMANATE?
A conventional ANDA-based generic launch is not the primary pathway. A competitor would generally need to pursue an applicable biologic licensing route and establish compliant plasma-derived manufacturing.
Does PLASMANATE have biosimilar competition?
There is no broadly established biosimilar market for PLASMANATE comparable to markets for monoclonal antibodies or recombinant proteins. The product’s complex plasma-derived composition makes direct follow-on development more difficult.
What is the main investment risk associated with PLASMANATE?
The main risk is commercial and operational rather than patent-related. Low volume, hospital substitution, plasma costs, manufacturing interruptions, and portfolio rationalization could reduce its contribution to Grifols’ plasma-products business.
References
-
DailyMed. (2024). PLASMANATE: Plasma Protein Fraction (Human), 5% prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
Grifols, S.A. (2023). Annual report 2023. https://www.grifols.com/
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2024). Biologics license applications and biological product regulation. https://www.fda.gov/
-
Plasma Protein Therapeutics Association. (2024). Plasma collection and plasma-derived medicinal products industry information. https://www.pptaglobal.org/
